An investigational small-molecule triple monoamine reuptake inhibitor (serotonin, noradrenaline, dopamine) studied as an appetite suppressant. Not a peptide and not FDA-approved, included here as an adjacent research compound.
Reviewed for accuracy · Last reviewed July 8, 2026Tesofensine is not a peptide. It is a small-molecule drug that blocks the reuptake of three neurotransmitters at once (serotonin, noradrenaline, and dopamine), which is thought to reduce appetite. It is included on this reference as an adjacent non-peptide research compound because it is discussed and sold alongside research peptides, much like SLU-PP-332.
Its main human evidence is a single Phase 2 obesity trial (TIPO-1), where once-daily oral doses produced dose-related weight loss over 24 weeks. It has never been FDA-approved, its planned Phase 3 program did not lead to approval, and more recent development in Latin America has not produced a verified regulatory approval, so everything here should be read as investigational.
The Phase 2 TIPO-1 trial studied once-daily oral doses of 0.25 mg, 0.5 mg, and 1 mg over 24 weeks. Tesofensine is investigational, so there is no approved prescribing dose.
Read the full Tesofensine dosage guide →In that trial the most common adverse events were dry mouth, nausea, constipation, hard stools, and insomnia. Heart rate rose in a dose-related way, most at the higher doses.
Read the full Tesofensine side effects guide →As a small-molecule compound it is generally kept in a cool, dry place away from light rather than reconstituted like a peptide. See the full storage & safety guide for handling and disposal basics.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Talk to a doctor before starting any compound.